First sale of complete solution validates Ikonisys business model and paves the way for accelerated business development
Paris, June 22, 2022 – 6 p.m. CEST – Ikonisys SA (ISIN Code: FR00140048X2 / Mnemonic: ALIKO), a company specializing in the early and precise detection of cancer with a unique fully automated solution for medical diagnostic laboratories, announces the first sale of its Ikoniscope20 digital fluorescence microscope solution with its optimized reagents.
As announced during Ikonisys’ IPO, the initial goal of the US go-to-market strategy is to convert current customers into Ikoniscope20 users. Active user of the old Ikoniscope Gen1 platform from Ikonisys until today, Comprehensive Urology decided to upgrade its system to the Ikoniscope20 and at the same time to use the optimized reagents provided by Ikonisys to carry out the diagnoses. molecules of bladder cancer.